#USA #oncology #Monmouth Junction #Creatv MicroTech #LifeTracDx

Creatv Bio Launches State-of-the-Art CLIA-Certified Laboratory

Creatv Bio, a division of Creatv MicroTech, Inc., has recently inaugurated its latest laboratory facility in Monmouth Junction, New Jersey. This new CLIA-certified laboratory marks a significant expansion in the company’s ability to support biopharma companies in the complex field of oncology drug development and clinical trials.

The newly established laboratory is equipped to offer Creatv's pioneering LifeTracDx® Blood Test, which is designed to detect two key components critical in cancer diagnostics: Cancer Associated Macrophage-Like cells (CAMLs) and Circulating Tumor Cells (CTCs). The significance of this test lies in its versatility; CAMLs can be detected in the bloodstream of a majority of cancer patients, across various malignancy subtypes, providing predictive insights regarding treatment response within a mere 30-45 days post-drug administration.

Key Advantages of LifeTracDx® Blood Test

The LifeTracDx® Blood Test presents several advantages tailored for oncology drug development, making it an invaluable tool for pharmaceutical stakeholders:

1. Monitors Early Treatment Response: Unlike traditional methods that evaluate drug efficacy at later stages, this blood test allows for early assessment, enabling more timely decisions regarding treatment adjustments.
2. Improves Patient Selection: By utilizing this test, sponsors can identify patients who are likely to respond positively to therapeutic interventions, thereby optimizing patient enrollment in clinical trials.
3. Companion and Complementary Diagnostics: The possibility of co-developing drugs that target specific tumor markers becomes feasible, as clinical effectiveness can be monitored through blood tests rather than invasive tissue samples.
4. Real-Time Biomarker Monitoring: The new facility facilitates continuous monitoring of biomarker expression in tumor cells, helping to immediately detect downregulation and resistance to therapies in real time.
5. PD-L1 Expression Measurement: Creatv is recognized as the first to provide a blood test for measuring changes in PD-L1 expression, which is crucial for assessing patient responses to PD-L1/PD-1 checkpoint inhibitors used in immunotherapy.

Dr. Cha-Mei Tang, President and CEO of Creatv Bio, expressed enthusiasm regarding the lab's opening, stating, "The establishment of our CLIA Laboratory enables us to offer comprehensive services that result in rapid and reliable analyses for our pharmaceutical partners. This development represents a crucial step forward in expediting cancer drug development."

Creatv Bio specializes in providing laboratory testing services to pharmaceutical companies for research-oriented and investigative purposes. While the LifeTracDx® blood test has been analytically validated and is utilized for research, it is important to note that it is not intended for use in clinical diagnosis or direct therapeutic management.

For those interested in exploring the scientific underpinnings of this groundbreaking technology, Creatv invites stakeholders to visit their website for access to peer-reviewed publications and detailed scientific posters related to their work.

As the fight against cancer continues to evolve, Creatv Bio’s innovative approaches and newly established facilities stand poised to make significant contributions to oncology drug development, advancing both patient care and clinical research in critical ways.